Skip to main content

Table 2 Summary of adverse events

From: Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine

  Cohort 1
(N=2)
Cohort 2
(N=2)
Cohort 3
(N=2)
Cohort 4b (N=2) Total
(N=8)
Number of subjects with at least one adverse event [n (%)]; number of adverse events
Any adverse event 2 (100%); 13 1 (50%); 3 2 (100%); 5 2 (100%); 23 7 (87.5%); 44
Adverse event of moderate intensity 1 (50%); 3 0 (0%); 0 1 (50%); 1 2 (100%); 3 4 (50%); 7
Adverse event of severe intensity 0 (0%); 0 0 (0%); 0 0 (0%); 0 1 (50%); 1a 1 (12.5%); 1a
Adverse event related to GAP vaccine 0 (0%); 0 0 (0%); 0 1 (50%); 1 2 (100%); 14 3 (37.5%); 15
Serious adverse event 0 (0%); 0 0 (0%); 0 0 (0%); 0 1 (50%); 1a 1 (12.5%); 1a
  1. aThe severe adverse event (joint dislocation) also met the criteria for a serious adverse event since it required hospitalization and surgery. This event was not considered related to the GAP vaccine. bOne subject in cohort 4 (subject 7) was confirmed to be positive for influenza B at the time of antimalarial treatment